Macquarie Group’s Niagen Bioscience NAGE Stock Holding History

Macquarie Group’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-606	Closed	-$2	–	2176
2024 Q1	$2	Buy	+606	New	+$1.12K	﹤0.01%	1860

Other funds holding NAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Macquarie Group's NAGE Position: Q2 2024 in Review

Macquarie Group sold out of Niagen Bioscience (NAGE) in Q2 2024, closing a stake of 606 shares — an estimated $2 sold.

Macquarie Group first reported a position in NAGE in Q1 2024 and held it in 1 quarter. The position peaked at $2 in Q1 2024. 78 funds tracked by Wall St. Rank hold NAGE as of Q2 2024.

Macquarie Group reported no remaining Niagen Bioscience position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 606 Niagen Bioscience shares in Q2 2024, an estimated $2.
Macquarie Group first reported a position in Niagen Bioscience in Q1 2024 and held it in 1 quarter.
Macquarie Group's Niagen Bioscience position peaked at $2 in Q1 2024.
78 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.